Company intelligence / Profile preview

Askur

Research Triangle Park, North Carolina, United Statesaskurgin.com ↗

Ownership: Private
Employees: ~501
Development stage: Commercial

Overview

AskBio recently published complete results of a Phase 1b trial of AB-1005 gene therapy for Parkinson’s disease showing the treatment was well tolerated with no serious adverse events related to GDNF gene therapy and evidence of clinical stability or improvement in motor function at 18 months post-transfer. The pipeline includes multiple programs across various stages targeting genetic diseases affecting CNS, muscle, respiratory and heart tissues.

Therapeutic areas: CardiovascularRare DiseasesNeurology
Modalities: Gene therapyBiologic
Industry: Biotech

Partnerships

Bayer AG (parent)technology licensed/acquired by PfizerTakedaNovartis/AveXis

Beyond the preview

Go deeper on Askur.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Askur.

Explore the full profile